169 related articles for article (PubMed ID: 28121937)
1. VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
Moon JY; Baek SW; Ryu H; Choi YS; Song IC; Yun HJ; Jo DY; Kim S; Lee HJ
Medicine (Baltimore); 2017 Jan; 96(4):e5942. PubMed ID: 28121937
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
[TBL] [Abstract][Full Text] [Related]
3. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
Kosmidis P; Mylonakis N; Fountzilas G; Pavlidis N; Samantas E; Karabelis A; Kattis K; Skarlos D
Ann Oncol; 1996 Jul; 7(5):517-20. PubMed ID: 8839908
[TBL] [Abstract][Full Text] [Related]
5. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
Issels RD; Prenninger SW; Nagele A; Boehm E; Sauer H; Jauch KW; Denecke H; Berger H; Peter K; Wilmanns W
J Clin Oncol; 1990 Nov; 8(11):1818-29. PubMed ID: 2121910
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
Fernberg JO; Wiklund T; Monge O; Hall KS; Saeter G; Alvegård TA; Strander H
Acta Orthop Scand Suppl; 1999 Jun; 285():62-8. PubMed ID: 10429625
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
13. ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children.
Aydin B; Akyuz C; Varan A; Yalcin B; Kurucu N; Kutluk T
Rev Recent Clin Trials; 2018; 13(2):126-131. PubMed ID: 29366426
[TBL] [Abstract][Full Text] [Related]
14. Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
Wang B; Yu X; Xu S; Xu M
Medicine (Baltimore); 2016 Jan; 95(4):e2611. PubMed ID: 26825914
[TBL] [Abstract][Full Text] [Related]
15. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
Hanna NH; Sandier AB; Loehrer PJ; Ansari R; Jung SH; Lane K; Einhorn LH
Ann Oncol; 2002 Jan; 13(1):95-102. PubMed ID: 11863118
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis.
Saito S; Aiba H; Yamada S; Okamoto H; Hayashi K; Kimura H; Miwa S; Otsuka T; Murakami H
BMC Cancer; 2020 Sep; 20(1):868. PubMed ID: 32907549
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
Wall N; Starkhammar H
Acta Oncol; 2003; 42(1):55-61. PubMed ID: 12665332
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Schütte J; Kellner R; Seeber S
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
